Guardant Health Hopes Lung Cancer Stakeholder Alignment Will Help Advance Liquid Biopsy Goals - GenomeWeb

Guardant Health Hopes Lung Cancer Stakeholder Alignment Will Help Advance Liquid Biopsy Goals  GenomeWeb

The firm has joined forces with AstraZeneca, the IASLC, and the Global Lung Cancer Coalition, with a goal to double five-year survival rates by 2025.



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Respirology | APSR Respiratory Medicine Journal